Calidi Biotherapeutics, Inc. announced that on May 10, 2024, Mr. David LaPre notified the Board of Directors of the company of his resignation as a director of the Company, including his position on each Board committee on which he served, effective immediately. Mr. LaPre?s resignation was not the result of any dispute or disagreement with the Company or the Company?s Board on any matter relating to the operations, policies or practices of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +10.55% |
|
+7.96% | -88.41% |
08/07 | Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin | CI |
05/07 | Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.41% | 11.23M | |
+20.63% | 127B | |
+25.01% | 27.67B | |
-20.17% | 20.33B | |
-16.71% | 16.79B | |
-18.07% | 15.63B | |
-47.70% | 14.65B | |
+11.92% | 14.84B | |
+58.32% | 14.43B | |
+149.98% | 12.49B |
- Stock Market
- Equities
- CLDI Stock
- News CALI BIOTPAR
- Calidi Biotherapeutics, Inc. Announces Resignation of David Lapre as Director